Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients

Transplantation

Volumn 92, Issue 6, 2011, Pages 648-652

  Wu, Ming Ju ^a,b,c,d   Cheng, Ching Yao ^a   Chen, Cheng Hsu ^a,e   Wu, Wen Pyng ^e,f   Cheng, Chi Hung ^a   Yu, Dong Ming ^a   Chuang, Ya Wen ^a   Shu, Kuo Hsiung ^a,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHANG BING SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Advagraf; Kidney transplantation; Tacrolimus; Trough level; Variability

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; EPIGASTRIC PAIN; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MODELS, STATISTICAL; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TACROLIMUS; TIME FACTORS;

EID: 80052688704     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182292426     Document Type: Article

References (29)

1. Dunn TB, Browne BJ, Gillingham KJ, et al. Selective retransplant after graft loss to nonadherence: Success with a second chance. Am J Transplant 2009; 9: 1337.
2. De Jonge H, Kuypers DR, Verbeke K, et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523.
3. Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: Experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007; 83: 1639.
4. Merli M, Di Menna S, Giusto M, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. Transplant Proc 2010; 42: 1322.
5. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007; 7: 1609.
6. Tinti F, Meçule A, Poli L, et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplant Proc 2010; 42: 4047.
7. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 1211.
8. Kahan BD, Welsh M, Urbauer DL, et al. Low intraindividual variability of cyclosporine A exposure reduces chronic rejection incidence and health care cost. J Am Soc Nephrol 2000; 11: 1122.
9. Waiser J, Slowinski T, Brinker-Paschke A, et al. Impact of the variability of cyclosporine A trough levels on long-term renal allograft function. Nephrol Dial Transplant 2002; 17: 1310.
10. De Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: Possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31: 416.
11. Cattaneo D, Merlini S, Pellegrino M, et al. Therapeutic drug monitoring of sirolimus: Effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004; 4: 1345.
12. Ming-Ju Wu, Kuo-Hsiung Shu, Jong-Da Lian, et al. Impact of variability of sirolimus trough level on chronic allograft nephropathy. Transplant Proc 2008; 40: 2202.
13. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757.
14. Jacobson PA, Oetting WS, Brearley AM, et al; DeKAF Investigators. Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300.
15. Dew MA, Dimartini AF. The incidence of nonadherence after organ transplant: Ensuring that our efforts at counting really count. Liver Transpl 2006; 12: 1736.
16. De Bleser L, Matteson M, Dobbels F, et al. Interventions to improve medication-adherence after transplantation: A systematic review. Transpl Int 2009; 22: 780.
17. Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation 2009; 88: 736.
18. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases.AmJ Manag Care 2009; 15: e22.
19. Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian Estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010; 49: 683.
20. Andres A, Delgado-Arranz M, Dipalma MT, et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: Singlecenter experience. Transplant Proc 2010; 42: 3034.
21. Chueh SCJ, Wang SM, Lai MK, et al. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. Transplant Proc 2004; 36: 2058.
22. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 867.
23. Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566.
24. Crespo M, Mir M, Marin M, et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009; 41: 2115.
25. First MR. First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit 2008; 30: 159.
26. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial. Am J Transplant 2009; 9: 2505.
27. Wallemacq P, Goffinet JS, O'Morchoe S, et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit 2009; 31: 198.
28. Canafax DM. Minimizing cyclosporine concentration variability to optimize transplant outcome. Clin Transplant 1995; 9: 1.
29. Biggerstaff BJ. Comparing diagnostic tests: A simple graphic using likelihood ratios. Stat Med 2000; 19: 649.